2023-04-21 07:53:42 ET
- Dr. Reddy's Laboratories ( NYSE: RDY ) said it launched Treprostinil Injection in the U.S. market.
- The drug is a generic version of United Therapeutics' ( NASDAQ: UTHR ) Remodulin (treprostinil) injection, which is approved in the U.S. to treat adults with pulmonary arterial hypertension — a type of high blood pressure which affects the arteries in the lungs and the right side of the heart.
- Dr. Reddy's noted that its Treprostinil Injection is supplied as 20 mg/20 mL, 50 mg/20 mL, 100 mg/20 mL or 200 mg/20 mL vials.
- RDY +0.18% to $59.77 premarket April 21
For further details see:
Dr. Reddy's launches generic version of hypertension drug Remodulin in US